

Concentrated Insulin

In order to allow for higher doses of insulin to be administered without resorting to multiple injections, some insulins are available in a concentrated format. To minimize the risk of error, concentrated insulin products are always supplied as a prefilled pen device.

Insulin is a **high-alert medication**, meaning that it has the potential to cause patient harm when administered in error. Insulin is one of the medications most frequently reported in harm incidents.¹

The Health PEI Formulary includes the following insulins that are available in multiple concentrations:

Insulin degludec: Tresiba[®] 100 unit/mL and Tresiba[®] 200 unit/mL

Insulin glargine: Lantus[®] (or Basaglar[®]) 100 unit/mL and Toujeo[®] 300 unit/mL

	IMPORTANT	
The dose	counter on the insulin pens shows the exact number of insulin units to	
be delivered to the patient. A unit is a unit, no matter the volume.		
NO ADJUSTMENT IS NECESSARY		

	Tresiba [®] FlexTouch 100 unit/mL	Tresiba [®] FlexTouch 200 unit/mL
Image	Insulin degluder	Insulin degludec insulin degludec insulin degludec instance
Pen Contains	300 total units	600 total units
Maximum single dose	80 units	160 units
Dose increments	1 unit	2 unit
Label	Light green	Dark green

Example:

If there is an order for 20 units, dial the pen to 20 units, no matter which concentration is used. **No dose calculation or adjustment is required**; the pen will adjust the volume to deliver the correct dose.

^{1.} Medications Most Frequently Reported in Harm Incidents over the Past 5 Years (2015 – 2020). *ISMP Canada Safety Bulletin*. vol. 20(11). December 22, 2020. https://ismpcanada.ca/wp-content/uploads/ISMPCSB2020-i11-Medications-Reported-Harm.pdf